A 13-year-old boy was diagnosed with AML after a short history of fatigue and pallor. A bone marrow examination demonstrated 40% myeloblasts with morphology consistent with FAB M2 subtype. Cytogenetics demonstrated a clonal abnormality with translocation between chromosomes 8 and 21. He was enrolled on the Childrens Oncology Group pilot study AAML03P1. Accordingly, he received initial induction chemotherapy, which comprised cytarabine 100 mg/m Following a conditioning regimen of busulfan 0.8 mg/kg/ dose i.v. four times daily on days À9, À8, À7, À6 and cyclophosphamide 50 mg/kg/dose daily on days À5, À4, À3, À2, he received 1.49 Â 10 8 nucleated cells/kg (2.27 Â 10 6 CD34 cells/kg) from his brother. Busulfan pharmacokinetic monitoring demonstrated an AUC of 1037 mM Á min (target 900-1350 mM Á min). Graft-versus-host disease (GvHD) prophylaxis was with cyclosporine and methotrexate. Ursodeoxycholic acid 150 mg orally twice a day was administered as VOD prophylaxis. He tolerated this conditioning therapy well, and the posttransplant course was unremarkable until day þ 11 when he developed jaundice, tender hepatomegaly, fluid retention and renal impairment. A clinical diagnosis of venoocclusive disease was supported by Doppler ultrasound findings of ascites and reversal of flow in the portal vein. He progressed to develop severe VOD with maximal weight gain 18% above baseline, peak bilirubin 67 mg/dl and multiorgan failure, necessitating peritoneal dialysis and ventilatory support. Treatment was initiated with antithrombin III infusions aiming to maintain a level above 120% and four doses of N-acetyl cysteine. There was no improvement in jaundice, and the direction of portal vein flow remained reversed. Neurological impairment was not appreciated until an initial attempt at extubation failed because of an inability to swallow secretions. The patient was also noted to be dysarthric at this time and was felt to have pseudobulbar palsy. He was re-intubated and, over the ensuing days, he developed increasing weakness of his upper limbs and horizontal gaze paralysis. Despite weaning his sedation, he became progressively less responsive, which precluded further attempts at extubation. An MRI scan of his brain demonstrated marked T2 hyperintensity in the pons, consistent with the diagnosis of central pontine myelinolysis (CPM) (Figure 1) . A review of serial serum sodium measurements revealed that they had fluctuated between 130-142 mEq/l during the 3 weeks of hospitalization prior to the MRI scan. During the same time period, serum magnesium levels varied between 1.6 and 3.0 mg/dl (reference range: 1.6-2.3 mg/dl) and cyclosporine levels were between 176 and 399 mcg/l. Peak serum ammonia level was 101 mmol/l (reference range: 10-35 mmol/l). The patient died 69 days post transplant as a result of hemodynamic instability in the setting of Candida sepsis and peritonitis.
CPM is a clinical syndrome consisting of spastic quadriplegia, ophthalmoplegia, pseudobulbar palsy and varying degrees of encephalopathy, which result from acute, non-inflammatory demyelination centered within the pons. 1 It often, but not always, occurs as a consequence of severe and prolonged hyponatremia, particularly when it is corrected too quickly. 2 The exact mechanism is unknown, but it is thought that cellular edema caused by fluctuating osmotic forces may trigger demyelination. 3 It is of note, though, that most patients with hyponatremia do not develop CPM and that some patients with relatively mild osmotic insults do, suggesting that there must be other predisposing factors. Other risk factors identified include alcoholism, malnutrition, liver disease and, interestingly, liver transplant. 2, 3 CPM has emerged as a well-recognized neurological complication following liver transplant. 4, 5 In one series of postmortem examinations of liver transplant patients, a 29% incidence of CPM was identified. Twothirds of those patients had had fluctuations in their serum sodium of less than 15-20 mEq/l. 6 It has been postulated that the use of cyclosporine following liver transplant increases the risk of development of CPM. 7 There is no specific treatment for CPM and the prognosis is poor although spontaneous improvement can occur. Survivors usually require prolonged rehabilitation and may have chronic neurologic deficits. 8 Neurological impairment was a prominent feature of our patient's post-transplant course. In such a critically ill patient, it is likely that several factors contributed to his encephalopathy, including liver dysfunction, hyperammonemia, uremia, sedative drugs and CPM. The correlation between cyclosporine neurotoxicity and serum levels is poor, and this agent may have contributed to the patient's encephalopathy, but the characteristic MRI finding of posterior leukoencephalopathy was absent. Other recognized causes of encephalopathy in the setting of hematopoietic stem cell transplantation (HSCT) include electrolyte disturbances, infection, cerebrovascular events or thrombotic thrombocytopenic purpura, but laboratory parameters and imaging findings did not support a role for these possibilities in this case. 9 Despite the likely multifactorial etiology of the encephalopathy, the signs of quadriplegia, ophthalmoplegia and pseudobulbar palsy in conjunction with suggestive neuroimaging are best explained by the diagnosis of CPM. To the best of our knowledge, CPM has not been previously described in the setting of HSCT. Our patient had not had any episodes of significant hyponatremia, although such electrolyte imbalances are not uncommon in the setting of HSCT. Given the known association with liver disease and liver transplantation, we hypothesize that his severe hepatic veno-occlusive disease and possibly cyclosporine therapy may have predisposed to the development of CPM. 
